Gene transfer for the therapy of hematologic malignancy.

H. E. Heslop, M. Roskrow

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Gene transfer has allowed a number of biologic issues in the therapy of hematologic malignancy to be addressed. In autologous bone marrow transplantation, gene marking studies have shown that infused marrow contributes to relapse in acute myeloid leukemia, neuroblastoma, and chronic myeloid leukemia. In addition, double gene marking with distinguishable retroviral vectors has allowed comparison of purging techniques and the ability of different sources of stem cells to repopulate. In allogeneic bone marrow transplantation, genetically modified T cells have proven valuable for the prophylaxis and treatment of viral diseases and may be of use to treat disease relapse. Gene transfer is also being used to modify tumor function, enhance immunogenicity, modify function of adoptively transferred immune system cells, and confer drug resistance to normal hematopoietic stem cells.

Original languageEnglish (US)
Pages (from-to)417-422
Number of pages6
JournalCurrent Opinion in Hematology
Issue number6
StatePublished - Nov 1995

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Gene transfer for the therapy of hematologic malignancy.'. Together they form a unique fingerprint.

Cite this